Latest news with #RelayTherapeutics
Business Insider
5 days ago
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX) and Relay Therapeutics (RLAY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report) and Relay Therapeutics (RLAY – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. OptimizeRx (OPRX) In a report released yesterday, Richard Baldry from Roth MKM reiterated a Buy rating on OptimizeRx, with a price target of $27.00. The company's shares closed last Thursday at $12.84, close to its 52-week high of $14.13. According to Baldry is a 5-star analyst with an average return of 17.4% and a 58.6% success rate. Baldry covers the Technology sector, focusing on stocks such as Zeta Global Holdings Corp, FiscalNote Holdings, and Research Solutions. Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $17.80, representing a 39.7% upside. In a report issued on August 4, Lake Street also maintained a Buy rating on the stock with a $19.00 price target. Relay Therapeutics (RLAY) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Relay Therapeutics yesterday. The company's shares closed last Thursday at $3.49, close to its 52-week low of $2.69. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 31.9% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.20, which is a 240.8% upside from current levels. In a report issued on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.50 price target.
Yahoo
29-07-2025
- Business
- Yahoo
Relay Therapeutics has positive read from Celcuity data, says Barclays
After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant Barclays analyst Peter Lawson said the data validate targeting the PI3K pathway in breast cancer, which has a positive read-through for Relay Therapeutics (RLAY). While gedatolisib could represent new competition, the firm continues to see important advantages in Relay's mutant selective approach and keeps an Overweight rating and $17 price target on Relay shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on RLAY: Disclaimer & DisclosureReport an Issue Claire Mazumdar Joins Relay Therapeutics as Director Relay Therapeutics Holds 2025 Annual Stockholder Meeting Relay Therapeutics Announces Lease Termination Agreement Relay Therapeutics announces updated data for RLY-2608 with Fulvestrant Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $17.00. The rating update came after the company announced updated interim clinical data for RLY-2608 on June 2. A chemist arranging containers of compounds, ready for the commercialization process. RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. The updated interim data remained consistent with the data previously shared in December 2024, showing a '10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.' The data continues to support the planned pivotal study initiation in mid-2025. Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company's Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $17.00. The rating update came after the company announced updated interim clinical data for RLY-2608 on June 2. A chemist arranging containers of compounds, ready for the commercialization process. RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. The updated interim data remained consistent with the data previously shared in December 2024, showing a '10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.' The data continues to support the planned pivotal study initiation in mid-2025. Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company's Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Boston Globe
17-06-2025
- Business
- Boston Globe
Isomorphic Labs sets up US presence in Cambridge, with an eye on clinical trials
After developing AlphaFold into a drug design platform, the company has entered the era where it is progressing some of those AI-enabled drug candidates toward clinical trials — and to do that, it needs a footprint in the United States. Isomorphic's move comes during a particularly turbulent period for the Advertisement Its first hire in Cambridge is Ben Wolf, who will work from the new office as the company's chief medical officer to build Isomorphic's clinical development team. Wolf was most recently CMO at Relay Therapeutics, whose cancer drug targets have been informed by computational discovery methods. At the end of March, Isomorphic Labs announced a Advertisement 'We're advancing quickly towards the clinic,' said Murdoch. 'As you think about the initial focus of the team in Boston and hiring of Ben, it hits squarely in that second bracket.' Earlier this year, Isomorphic announced development partnerships with US-based Eli Lilly and Switzerland-based Novartis worth $82.5 million up front, with nearly $3 billion in potential value. It also has internal assets in development in oncology and immunology. 'Whether they're headquartered in Boston or not, they've got a strong presence there, so it's helpful to be close to our partners,' said Murdoch, who declined to project clinical timelines for any of the drug candidates. Isomorphic's new office — which has yet to find a permanent home — comes at a The Cambridge office will start small, with up to a dozen employees focused on getting trials off the ground. That's less than a tenth of Isomorphic's total headcount, with about 200 employees concentrated in a central London office and to a smaller extent, in a newer office in Lausanne, Switzerland. Later on, the Cambridge office plans to recruit in other areas — including medicinal chemistry, machine learning, and computational biology — as it continues developing its drug engines. Earlier iterations focused on small molecule drugs, the target of Isomorphic's current pharma partnerships, but the company has expanded to biologics. 'Technically, the platform models everything in terms of atoms,' said Murdoch. 'Biologics and small molecules look pretty much the same when you look at them at that level.' Advertisement Despite Wolf's clinical development expertise, Murdoch said the chief medical officer would also be involved in moving Isomorphic's drug engine forward. 'It sounds a bit out of sequence, because you would normally think about it as a linear process,' he said. But 'in the end, what we're trying to do is create drugs that do work in humans in the clinic. So why not bring forward those insights at the beginning?'
